Isolation and identification of SARS-CoV-2 antibodies from COVID-19 patient samples

Isolation and identification of SARS-CoV-2 antibodies from COVID-19 patient samples

<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causing agent for COVID-19, has led to over 7 million deaths since it was first detected in Wuhan, China in December 2019. Antibodies induced by both vaccination and infection are crucial for the immune protection ag...

Полное описание

Библиографические подробности
Главный автор:	Liu, C
Другие авторы:	Screaton, GR
Формат:	Диссертация
Язык:	English
Опубликовано:	2024
Предметы:	Immunology

Схожие документы

SARS-CoV-2 infection induces robust mucosal antibody responses in the upper respiratory tract
по: Alba Escalera, и др.
Опубликовано: (2024-03-01)

Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection
по: Xiao-Lin Jiang, и др.
Опубликовано: (2024-07-01)

Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2
по: Cyril Planchais, и др.
Опубликовано: (2024-07-01)

SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness
по: Jeewandara, C, и др.
Опубликовано: (2021)

Cross-reactive immunity to SARS-CoV-2 and related coronaviruses
по: Jay, C
Опубликовано: (2023)

Nonhuman primate antigenic cartography of SARS-CoV-2
по: Annika Rössler, и др.
Опубликовано: (2025-01-01)

Studies on immunoreceptor activation and SARS-CoV-2 RBD/ACE2 interactions
по: Barton, MI
Опубликовано: (2022)

Anti-SARS-CoV-2 antibodies in a nasal spray efficiently block viral transmission between ferrets
по: Kiira Gildemann, и др.
Опубликовано: (2024-07-01)

SARS-CoV-2 produces a microRNA CoV2-miR-O8 in patients with COVID-19 infection
по: Elise J. Tucker, и др.
Опубликовано: (2024-01-01)

Epitopes recognition of SARS-CoV-2 nucleocapsid RNA binding domain by human monoclonal antibodies
по: Youngchang Kim, и др.
Опубликовано: (2024-02-01)

Development of human monoclonal antibodies against SARS-CoV-2
по: Wong, Joel Xu En
Опубликовано: (2021)

SARS-CoV-2 infection elucidates features of pregnancy-specific immunity
по: Dong Sun Oh, и др.
Опубликовано: (2024-11-01)

Multivariate analyses and machine learning link sex and age with antibody responses to SARS-CoV-2 and vaccination
по: Miroslava Cuperlovic-Culf, и др.
Опубликовано: (2024-08-01)

Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies
по: Tetsuya Inoue, и др.
Опубликовано: (2024-04-01)

Increasing Sporadic Covid-19 Cases:Should We Heed Airborne Transmission Of SARS-CoV-2?
по: Ahmad Mahfuz, Gazali
Опубликовано: (2021)

An unconventional VH1-2 antibody tolerates escape mutations and shows an antigenic hotspot on SARS-CoV-2 spike
по: Banghui Liu, и др.
Опубликовано: (2024-06-01)

Characterisation of HBV and SARS-CoV-2 spike specific T cells and their association with viral control
по: Liu, G
Опубликовано: (2023)

Functional diversification of innate and inflammatory immune responses mediated by antibody fragment crystallizable activities against SARS-CoV-2
по: Martina Severa, и др.
Опубликовано: (2024-05-01)

SARS-CoV-2 vaccine development and challenges
по: Duan Fugang, и др.
Опубликовано: (2021-03-01)

Elucidating factors of heterogeneous immune response to SARS-CoV-2 and human immunodeficiency virus
по: Lim, N
Опубликовано: (2024)

Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1
по: Zhou Tong, и др.
Опубликовано: (2024-06-01)

SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity
по: Elizabeth J. Martinez, и др.
Опубликовано: (2024-10-01)

Variant- and vaccination-specific alternative splicing profiles in SARS-CoV-2 infections
по: Sung-Gwon Lee, и др.
Опубликовано: (2024-03-01)

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV
по: Cara W. Chao, и др.
Опубликовано: (2024-12-01)

SARS-CoV-2 antigen-carrying extracellular vesicles activate T cell responses in a human immunogenicity model
по: Sarah E. Cummings, и др.
Опубликовано: (2024-01-01)

A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta
по: Carter, Brandon, и др.
Опубликовано: (2023)

tANCHOR-cell-based assay for monitoring of SARS-CoV-2 neutralizing antibodies rapidly adaptive to various receptor-binding domains
по: Daniel Ivanusic, и др.
Опубликовано: (2024-03-01)

Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1
по: Alexander Muik, и др.
Опубликовано: (2024-08-01)

Convergence of SARS-CoV-2 spike antibody levels to a population immune setpointResearch in context
по: Eric J. Nilles, и др.
Опубликовано: (2024-10-01)

Characterising the T cell responses to SARS-CoV-2 including variants of concern induced by natural infection and vaccines
по: Adele, S
Опубликовано: (2024)

Differential immunometabolic responses to Delta and Omicron SARS-CoV-2 variants in golden syrian hamsters
по: Rajesh Rajaiah, и др.
Опубликовано: (2024-08-01)

Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion
по: Lu Zhang, и др.
Опубликовано: (2024-06-01)

Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection
по: Mohamed I.M. Ahmed, и др.
Опубликовано: (2024-06-01)

Immune imprinting of SARS-CoV-2 responses: changing first immune impressions
по: J. Torresi, и др.
Опубликовано: (2024-04-01)

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine
по: Masayuki Aboshi, и др.
Опубликовано: (2024-02-01)

A systems biology approach to define SARS-CoV-2 correlates of protection in non-human primates
по: Brady, C
Опубликовано: (2024)

The alarmin IL-33 exacerbates pulmonary inflammation and immune dysfunction in SARS-CoV-2 infection
по: Hui Wang, и др.
Опубликовано: (2024-06-01)

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
по: Willett, BJ, и др.
Опубликовано: (2022)

SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
по: Hirsch, C, и др.
Опубликовано: (2021)

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
по: Kreuzberger, N, и др.
Опубликовано: (2021)